Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
This article was originally published in RPM Report
Executive Summary
The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.
You may also be interested in...
So That's What "Non-Interference" Means: CMS Defines Loaded Term in Proposed Part D Rule
The 700-page Part D proposed rule does much more than change the "protected" class list. Among many other provisions, it spells out how CMS interprets the infamous "non-interference" clause.
Part D Rebates: Defeat In Finance Committee May Set Key Precedent
Democratic Sen. Bill Nelson of Florida may have made a tactical error in bringing up an amendment to mandate drug rebates under Medicare Part D during the Senate Finance Committee’s markup of health reform legislation.
Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't
The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.